FDA — authorised 26 October 2023
- Application: BLA761279
- Marketing authorisation holder: ELI LILLY AND CO
- Local brand name: OMVOH
- Indication: VIAL — SINGLE-USE
- Status: approved
The FDA approved OMVOH, a drug developed by ELI LILLY AND CO, on 2024-04-29. The approval was granted under the standard expedited pathway. The marketing authorisation holder is ELI LILLY AND CO, and the indication approved is for labeling.